A recent study from the Department of Systems Medicine, University of Tor Vergata, Italy shows that Mongersen, an oral SMAD7 antisense oligonucleotide, inhibits regional enteritis disease. This study was published in the 19 March 2015 issue of of the Journal “N. Engl. J. Med.” [I.F: 54.42] by Prof Pallone F., Monteleone G, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Treating regional enteritis disease with an anticancer drug: Campothecin (CPT) increases the expression of immunosuppressive cytokine TGF-β1 and inhibits the progression of regional enteritis disease via up regulation of its target gene. By treating regional enteritis patients with Campothecin (CPT), one may increase the expression of immunosuppressive cytokine transforming growth factor β1 (TGF-β1) and suppress inflammation. Together, this study suggests, for the first time, that pharmacological formulations encompassing “Campothecin (CPT) or its analogues” may be used to inhibit the progression of regional enteritis disease.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed information: How Campothecin (CPT) inhibits the progression of regional enteritis disease
To cite: Boominathan, Treating regional enteritis disease with an anticancer drug: Campothecin (CPT) increases the expression of immunosuppressive cytokine TGF-β1 and inhibits the progression of regional enteritis disease via up regulation of its target gene, 8/April/2015, 23.41, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation